Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240 A Randomized Double-Blind Phase III Trial [featured_image] Download is available until [expire_date] Version Download 1 File Size 794.48 KB File Count 1 Create Date 29/09/2022 Last Updated 29/09/2022 Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240 A Randomized Double-Blind Phase III Trial